Gene panel sequencing (NGS) presents the likelihood to research uncommon types of monogenic diabetes (MgD). To that finish, 18 genes had been analyzed in 1676 sufferers referred for MODY genetic testing.Among the many 307 sufferers with a molecular prognosis of MgD, 55 (17.9%) had been mutated in a gene related to a genetic syndrome.
Eight % (n=25) of the sufferers with mutations carried the m.3243A>G variant related to MIDD (Maternally inherited diabetes and deafness). At time of referral little or no had reported listening to loss or some other component of the everyday syndromic presentation.
Six % of the sufferers had been mutated in HNF1B regardless that the everyday extra-pancreatic options weren’t identified at time of referral. Surprisingly the third most distinguished etiology in these uncommon types was the WFS1 gene accounting for two.9% of the sufferers with pathogenic mutations (n=9).
None of them depicted a Wolfram syndrome presentation regardless that some options had been reported in 6/9 sufferers.Proscribing the evaluation of sure genes to sufferers with the respective particular phenotypes would miss out these with partial shows.
These outcomes subsequently underlie the undisputable good thing about NGS methods regardless that the scenario implies cascade penalties each for the molecular biologist and the clinician. Unbiased determinants of cIMT in keeping with the regression fashions had been solely gender sort of glucose monitoring and central systolic BP (cSBP).
Syntaxin Four enrichment in β-cells prevents conversion to autoimmune diabetes in non-obese diabetic (NOD) mice
Syntaxin 4 (STX4), a plasma membrane-localized SNARE protein, regulates human islet β-cell insulin secretion and preservation of β-cell mass. We discovered that human sort 1 diabetic (T1D) and non-obese diabetic (NOD) mouse islets present decreased β-cell STX4 expression, in line with decreased STX4 expression as a possible driver of T1D phenotypes.
Of NOD-iβSTX4 mice, 73% had sustained normoglycemia versus <20% of management NOD (NOD-Ctrl) mice, by 25 weeks of age. At 12 weeks of age, previous to diabetes conversion, NOD-iβSTX4 mice demonstrated superior whole-body glucose tolerance and β-cell glucose responsiveness than NOD-Ctrl mice.
Greater β-cell mass and decreased β-cell apoptosis had been additionally detected in NOD-iβSTX4 pancreata in contrast with these of NOD-Ctrl mice. To check this speculation, we generated inducible β-cell-specific STX4-expressing NOD mice.
Single-cell RNA-sequencing revealed that islets from NOD-iβSTX4 had markedly decreased IFNγ signaling and TNFα signaling by way of NF-ĸB in islet β-cells, together with decreased expression of the chemokine CCL5; CD4+ Treg cells had been additionally enriched in NOD-iβSTX4 islets.
These outcomes present a deeper mechanistic understanding of STX4 perform in β-cell safety and warrant additional investigation of STX4 enrichment as a technique to reverse or forestall T1D in people or defend β-cell grafts.
This was a cross-sectional case-control examine. In complete, 192 sufferers and 188 wholesome controls had been enrolled from the Pediatric Diabetes Clinic at King Salman Navy Hospital between January 2000 and December 2010. Detailed sufferers’ information recorded whereas distributing questionnaires to regulate samples included varied gradations of consanguinity and household histories of T1DM and autoimmune illness.
No consensus was discovered within the Swedish tips for any of the 31 variables. Some tips had been contradictory. The being pregnant tips had been adopted in 17.5% of the medical data, 18.4% adopted the labor tips, and 5.3% adopted each tips. The onset of labor, mode of supply and HbA1c within the third trimester different considerably, relying on the adherence to tips.
Steady Blood Glucose Monitoring Will increase Vigorous Bodily Exercise Ranges and Is Related With Diminished Hypoglycemia Avoidance Habits In Youth With Kind 1 Diabetes
The first purpose of this examine was to discover bodily exercise (PA) ranges, hypoglycemia concern scores and hypoglycemia episodes in keeping with insulin administration and blood glucose monitoring strategies in youth with sort 1 diabetes (T1D). A self-administered questionnaire was accomplished by 28 kids and 33 adolescents with T1D, and their PA was assessed.
Hypoglycemia episodes, concern of hypoglycemia scores, insulin remedy (pump vs. injection) and blood glucose monitoring (steady blood glucose screens [CGMs] vs. blood glucose meters) strategies are reported within the current work.
There have been no vital variations within the variety of hypoglycemic episodes, little one hypoglycemia concern survey conduct or complete scores, or any elements of the PA profile between youth utilizing injections and people utilizing a pump. CGM use correlated considerably with VPA ranges (β=0.6; p=0.04).
Greater VPA ranges had been related to larger little one hypoglycemia concern survey conduct scores (β=0.52; p=0.04). The latter correlates negatively with the variety of episodes of hypoglycemia previously 12 months in all class teams. The kind of insulin injection was not related to extra exercise in youth with T1D.
In distinction, CGM use could also be related to elevated vigorous PA amongst T1D youth. These with larger hypoglycemia concern survey conduct scores engaged in additional VPA and had fewer hypoglycemia episodes. Though CGM use ensures steady monitoring of glycemia throughout train, growing hypoglycemia avoidance conduct remains to be a crucial a part of train administration methods in energetic youth with T1D.
Central Systolic Blood Strain Is Related With Early Vascular Harm in Kids and Adolescents With Kind 1 Diabetes
Carotid intima-media thickness (cIMT), carotid distensibility coefficient (cDC), and carotid-femoral pulse wave velocity (PWV) had been measured in kids and adolescents with T1D, in a follow-up on the outpatient clinics of Verona.
Blood strain (BP; each central and peripheral), metabolic and different cardiovascular threat components had been evaluated in multivariate linear regressions to evaluate the affiliation with the measured indices of subclinical vascular injury.
100 and twenty-six kids and adolescents had been included. cIMT was above the 95th percentile for age and top in 60.8% of the inhabitants, whereas 26% of the pattern had cDC impairment (lower than the fifth percentile) and 4.8% had an elevated PWV.
PWV was related to age, intercourse, coronary heart charge, and cSBP; cDC with age and each cSBP and, alternatively, peripheral BP (pBP). Neither pBP nor any of the examined metabolic parameters, together with glycated hemoglobin, was related to PWV and cIMT.
RRAD antibody |
70R-5797 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
RRAD antibody |
70R-5798 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
RRAD Antibody |
37229-100ul |
SAB |
100ul |
EUR 302.4 |
RRAD Antibody |
CSB-PA233809- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
RRAD Conjugated Antibody |
C37229 |
SAB |
100ul |
EUR 476.4 |
Polyclonal RRAD Antibody |
APR05556G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications: |
RRAD siRNA |
20-abx932133 |
Abbexa |
|
|
|
RRAD Peptide |
43-008P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: RRAD Peptide |
RRAD Blocking Peptide |
33R-4793 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797 |
RRAD Blocking Peptide |
33R-10070 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798 |
RRAD Blocking Peptide |
20-abx063234 |
Abbexa |
|
|
|
Polyclonal Goat anti-GST α-form |
GST-ANTI-1 |
Detroit R&D |
50 uL |
EUR 336 |
Polyclonal Goat anti-GST μ-form |
GST-ANTI-2 |
Detroit R&D |
50 uL |
EUR 336 |
Polyclonal Goat anti-GST p-form |
GST-ANTI-3 |
Detroit R&D |
50 uL |
EUR 336 |
Human RRAD shRNA Plasmid |
20-abx954199 |
Abbexa |
|
|
|
RRAD Recombinant Protein (Human) |
RP095493 |
ABM |
100 ug |
Ask for price |
RRAD Recombinant Protein (Rat) |
RP226925 |
ABM |
100 ug |
Ask for price |
RRAD Recombinant Protein (Mouse) |
RP169340 |
ABM |
100 ug |
Ask for price |
GTP-Binding Protein RAD (RRAD) Antibody |
20-abx008742 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
GTP-binding protein RAD (RRAD) Antibody |
abx332370-100ul |
Abbexa |
100 ul |
EUR 510 |
|
GTP-Binding Protein RAD (RRAD) Antibody |
abx432011-200ul |
Abbexa |
200 ul |
EUR 460.8 |
|
GTP-binding protein RAD (RRAD) Antibody |
20-abx324872 |
Abbexa |
|
|
|
GTP-binding protein RAD (RRAD) Antibody |
20-abx241706 |
Abbexa |
|
|
|
GTP-binding protein RAD (RRAD) Antibody |
20-abx214509 |
Abbexa |
|
|
|
Rrad ORF Vector (Rat) (pORF) |
ORF075643 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Rrad ORF Vector (Mouse) (pORF) |
ORF056448 |
ABM |
1.0 ug DNA |
EUR 607.2 |
RRAD ORF Vector (Human) (pORF) |
ORF031832 |
ABM |
1.0 ug DNA |
EUR 486 |
Polyclonal RRAD (aa36-48) Antibody (internal region) |
APG00807G |
Leading Biology |
0.1mg |
EUR 580.8 |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications: |
RRAD And GEM Like GTPase 2 (REM2) Antibody |
abx122938-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
RRAD And GEM Like GTPase 2 (REM2) Antibody |
abx237237-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
Rrad sgRNA CRISPR Lentivector set (Rat) |
K7052701 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Rrad sgRNA CRISPR Lentivector set (Mouse) |
K3480701 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
RRAD sgRNA CRISPR Lentivector set (Human) |
K2069901 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 1) |
K7052702 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 2) |
K7052703 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 3) |
K7052704 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K3480702 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K3480703 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K3480704 |
ABM |
1.0 ug DNA |
EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
K2069902 |
ABM |
1.0 ug DNA |
EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
K2069903 |
ABM |
1.0 ug DNA |
EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
K2069904 |
ABM |
1.0 ug DNA |
EUR 184.8 |
RRAD Protein Vector (Human) (pPB-C-His) |
PV127326 |
ABM |
500 ng |
EUR 662.4 |
RRAD Protein Vector (Human) (pPB-N-His) |
PV127327 |
ABM |
500 ng |
EUR 662.4 |
RRAD Protein Vector (Human) (pPM-C-HA) |
PV127328 |
ABM |
500 ng |
EUR 662.4 |
RRAD Protein Vector (Human) (pPM-C-His) |
PV127329 |
ABM |
500 ng |
EUR 662.4 |
RRAD Protein Vector (Rat) (pPB-C-His) |
PV302570 |
ABM |
500 ng |
EUR 723.6 |
RRAD Protein Vector (Rat) (pPB-N-His) |
PV302571 |
ABM |
500 ng |
EUR 723.6 |
RRAD Protein Vector (Rat) (pPM-C-HA) |
PV302572 |
ABM |
500 ng |
EUR 723.6 |
RRAD Protein Vector (Rat) (pPM-C-His) |
PV302573 |
ABM |
500 ng |
EUR 723.6 |
RRAD Protein Vector (Mouse) (pPB-C-His) |
PV225790 |
ABM |
500 ng |
EUR 723.6 |
RRAD Protein Vector (Mouse) (pPB-N-His) |
PV225791 |
ABM |
500 ng |
EUR 723.6 |
RRAD Protein Vector (Mouse) (pPM-C-HA) |
PV225792 |
ABM |
500 ng |
EUR 723.6 |
RRAD Protein Vector (Mouse) (pPM-C-His) |
PV225793 |
ABM |
500 ng |
EUR 723.6 |
Rrad 3'UTR Luciferase Stable Cell Line |
TU219725 |
ABM |
1.0 ml |
Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
TU168183 |
ABM |
1.0 ml |
Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
TU269725 |
ABM |
1.0 ml |
Ask for price |
Rrad 3'UTR Luciferase Stable Cell Line |
TU118183 |
ABM |
1.0 ml |
Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
TU072380 |
ABM |
1.0 ml |
EUR 1672.8 |
RRAD 3'UTR Luciferase Stable Cell Line |
TU022380 |
ABM |
1.0 ml |
EUR 1672.8 |
Human GTP-binding protein RAD (RRAD) ELISA Kit |
abx385354-96tests |
Abbexa |
96 tests |
EUR 1093.2 |
|
Rat GTP-binding protein RAD (RRAD) ELISA Kit |
abx391893-96tests |
Abbexa |
96 tests |
EUR 1093.2 |
|
Mouse GTP-binding protein RAD (RRAD) ELISA Kit |
abx390415-96tests |
Abbexa |
96 tests |
EUR 1093.2 |
|
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV658369 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RRAD Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV658373 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RRAD Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
LV658374 |
ABM |
1.0 ug DNA |
EUR 616.8 |
Human GTP- binding protein RAD, RRAD ELISA KIT |
ELI-35549h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Mouse GTP- binding protein RAD, Rrad ELISA KIT |
ELI-14089m |
Lifescience Market |
96 Tests |
EUR 1038 |
Human RRAD And GEM Like GTPase 2 (REM2) ELISA Kit |
abx382769-96tests |
Abbexa |
96 tests |
EUR 1093.2 |
|
Rrad ELISA Kit| Mouse GTP-binding protein RAD ELISA Kit |
EF016057 |
Lifescience Market |
96 Tests |
EUR 826.8 |
Rrad ELISA Kit| Rat GTP-binding protein RAD ELISA Kit |
EF019253 |
Lifescience Market |
96 Tests |
EUR 826.8 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
K7052705 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
K3480705 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
K2069905 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
LV658370 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
LV658371 |
ABM |
1.0 ug DNA |
EUR 686.4 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV658372 |
ABM |
1.0 ug DNA |
EUR 686.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
K7052706 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
K7052707 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
K7052708 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K3480706 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
K3480707 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
K3480708 |
ABM |
1.0 ug DNA |
EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
K2069906 |
ABM |
1.0 ug DNA |
EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
K2069907 |
ABM |
1.0 ug DNA |
EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
K2069908 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Anti-Anti-SEPT6 antibody antibody |
STJ11100949 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
STJ111369 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT4 Antibody antibody |
STJ112276 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-SEPT5 Antibody antibody |
STJ25477 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
STJ25479 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT7 Antibody antibody |
STJ28963 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT1 antibody antibody |
STJ119580 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
Anti-Anti-SEPT12 Antibody antibody |
STJ117759 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT5 Antibody antibody |
STJ114819 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT7 Antibody antibody |
STJ116214 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
STJ117206 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-DDB1 Antibody |
A00333 |
BosterBio |
100uL |
EUR 546 |
Description: Rabbit Polyclonal DDB1 Antibody. Validated in IP and tested in Human, Mouse. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
AEA465Hu-10x96wellstestplate |
Cloud-Clone |
10x96-wells test plate |
EUR 6777.36 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
AEA465Hu-1x48wellstestplate |
Cloud-Clone |
1x48-wells test plate |
EUR 663.31 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
AEA465Hu-1x96wellstestplate |
Cloud-Clone |
1x96-wells test plate |
EUR 896.16 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
AEA465Hu-5x96wellstestplate |
Cloud-Clone |
5x96-wells test plate |
EUR 3672.72 |
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
4-AEA465Hu |
Cloud-Clone |
-
EUR 6837.60
-
EUR 3613.20
-
EUR 896.40
|
- 10 plates of 96 wells
- 5 plates of 96 wells
- 1 plate of 96 wells
|
|
Description: Enzyme-linked immunosorbent assay based on the Competitive Inhibition method for detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in samples from serum, plasma and other biological fluids with no significant corss-reactivity with analogues from other species. |
ELISA kit for Human Anti-AsAb (Anti-Anti-Sperm Antibody Antibody) |
ELK8071 |
ELK Biotech |
1 plate of 96 wells |
EUR 518.4 |
|
Description: A competitive Inhibition ELISA kit for detection of Anti-Anti-Sperm Antibody Antibody from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids. |
Anti-H4K20me1 Antibody |
CI1005 |
BosterBio |
100ul |
EUR 589.2 |
Description: Rabbit Polyclonal H4K20me1 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human. |
Anti-H4K20me3 Antibody |
CI1011 |
BosterBio |
100ul |
EUR 589.2 |
Description: Rabbit Polyclonal H4K20me3 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human. |
Anti-TIP5 Antibody |
CI1016 |
BosterBio |
100ul |
EUR 589.2 |
Description: Rabbit Polyclonal TIP5 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human, Mouse. |
Anti-H4K8ac Antibody |
CI1021 |
BosterBio |
100ul |
EUR 589.2 |
Description: Rabbit Polyclonal H4K8ac Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human. |
Anti-MYH11 Antibody |
CI1028 |
BosterBio |
100ul |
EUR 589.2 |
Description: Rabbit Polyclonal MYH11 Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IHC, WB and tested in Human. |
Anti-Ski3 Antibody |
CI1031 |
BosterBio |
150ug/50ul |
EUR 589.2 |
Description: Rabbit Polyclonal Ski3 Antibody. Validated in ChIP, ChIP-qPCR, IF, IHC, WB and tested in Human. |
Anti-Ski8 Antibody |
CI1032 |
BosterBio |
150ug/60ul |
EUR 589.2 |
Description: Rabbit Polyclonal Ski8 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Drosophila, Human. |
A excessive proportion of early vascular injury, particularly an elevated cIMT, is current in kids and adolescents with T1D in whom cSBP appears to be a standard determinant. In kids and adolescents with T1DM, a particular focus must be on hemodynamic threat components past metabolic ones.
Source :